1. Project Description:

RSI Project in Aggregation in Effective Collaboration between OPBG, IFO-IRE, TAKIS, and PLAISANT

CUP Code: E82F20000240002

Public Notice “Strategic Projects” year 2019 – POR FESR Lazio 2014-2020

Application No. A0320-2019-28114

2. Partners:

• Bambino Gesù Children’s Hospital (OPBG)
• Institutes for Research and Hospitalization – Regina Elena National Cancer Institute and San Gallicano Dermatological Institute (IFO-IRE)
• Takis S.r.l.
• Plaisant S.r.l.

3. Purpose:

The project, aimed at developing new therapies in oncohematology, aims to develop prototypes of gene therapy based on the generation of genetically modified cells expressing chimeric receptors for the HER-3 antigen “HE3-CAR” for the treatment of patients with sarcoma.

4. Results:

Characterization of specific antibodies for the HER3 antigen (Takis)

Validation of HER3 expression in silico and in tumor tissues from adult or pediatric sarcoma patients (IFO)

Generation of a mouse model for sarcoma in combination with HER3 antibodies (Plaisant)

Generation of HER3 CAR prototypes (OPBG)

Generation of small and large-scale procedures to obtain CAR.HER3 with high anti-tumor activity tested in in vitro models (OPBG)

In vivo functional study of CAR HER3 vs Sarcomas to collect preliminary data on the prototype’s efficacy and safety (OPBG/Plaisant)

Financial support received:

€609,791.87